Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
Journal
JTO clinical and research reports
Journal Volume
3
Journal Volume
3
Journal Issue
11
Journal Issue
11
Start Page
論文號碼 100405
ISSN
2666-3643
Date Issued
2022-11
Author(s)
Abstract
Although driver gene mutations have been believed to be mutually exclusive, some patients with NSCLC and concomitant EGFR mutations and EML4-ALK rearrangements have been reported. In this study, we reported a case of a patient with lung cancer who harbored both EGFR mutation and the EML4-ALK rearrangement after acquiring resistance to the EGFR tyrosine kinase inhibitor treatment. EGFR-mutant and ALK fusion proteins were detected in the same tumor cells through immunohistochemical analysis. Investigation of the molecular mechanisms of concomitant EGFR mutation and the EML4-ALK rearrangement in the same tumor cell can help discover an appropriate treatment for these patients.
Subjects
ALK inhibitor; EGFR; EGFR-TKI; EML4-ALK; Lung cancer
SDGs
Type
journal article